EP 3962497 A4 20230118 - ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
Title (en)
ENGINEERED CHIMERIC FUSION PROTEIN COMPOSITIONS AND METHODS OF USE THEREOF
Title (de)
GENTECHNISCH HERGESTELLTE CHIMÄRE FUSIONSPROTEINZUSAMMENSETZUNGEN UND VERFAHREN ZU DEREN VERWENDUNG
Title (fr)
COMPOSITIONS DE PROTÉINES DE FUSION CHIMÉRIQUES MODIFIÉES ET LEURS PROCÉDÉS D'UTILISATION
Publication
Application
Priority
- US 201962841190 P 20190430
- US 201962841183 P 20190430
- US 202016827381 A 20200323
- US 202016827302 A 20200323
- US 2020030837 W 20200430
Abstract (en)
[origin: WO2020223550A1] The present disclosure provides compositions and methods for making and using engineered phagocytic cells that express a chimeric antigen receptor having an enhanced phagocytic activity for immunotherapy in cancer or infection.
IPC 8 full level
A61K 35/15 (2015.01); A61K 9/00 (2006.01); A61K 31/7088 (2006.01); A61K 38/15 (2006.01); A61K 38/19 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01)
CPC (source: EP GB IL KR)
A61K 9/0019 (2013.01 - EP GB IL); A61K 31/7088 (2013.01 - EP GB IL); A61K 38/1774 (2013.01 - KR); A61K 38/19 (2013.01 - EP GB IL); A61K 39/3955 (2013.01 - KR); A61K 39/4614 (2023.05 - EP GB IL KR); A61K 39/4622 (2023.05 - EP GB IL KR); A61K 39/4631 (2023.05 - EP GB IL KR); A61K 39/464402 (2023.05 - EP GB IL KR); A61K 39/464406 (2023.05 - EP GB IL KR); A61K 39/464461 (2023.05 - EP GB IL KR); A61K 39/464466 (2023.05 - EP GB IL KR); A61K 48/005 (2013.01 - KR); A61P 35/00 (2018.01 - EP KR); C07K 14/7051 (2013.01 - EP GB IL KR); C07K 16/00 (2013.01 - KR); C07K 16/2896 (2013.01 - IL KR); C07K 16/32 (2013.01 - IL KR); A61K 2039/505 (2013.01 - KR); A61K 2239/31 (2023.05 - EP GB IL KR); A61K 2239/38 (2023.05 - EP GB IL KR); A61K 2239/48 (2023.05 - EP GB IL KR); A61K 2300/00 (2013.01 - IL); C07K 16/2896 (2013.01 - EP GB); C07K 16/32 (2013.01 - EP GB); C07K 2317/622 (2013.01 - EP GB IL KR); C07K 2317/73 (2013.01 - KR); C07K 2319/03 (2013.01 - EP GB IL KR); C07K 2319/033 (2013.01 - EP GB IL)
C-Set (source: EP)
Citation (search report)
- [Y] WO 2016172606 A1 20161027 - BAYLOR COLLEGE MEDICINE [US]
- [Y] US 2018244748 A1 20180830 - GILL SAAR [US], et al
- [Y] WO 2018140831 A2 20180802 - SILVERBACK THERAPEUTICS INC [US]
- [Y] WO 2017025944 A2 20170216 - UNIV BRIGHAM YOUNG [US]
- [Y] US 2018186855 A1 20180705 - ROSENTHAL ARNON [US]
- [A] DE KLEER ISMÃ ET AL: "Ontogeny of Myeloid Cells", FRONTIERS IN IMMUNOLOGY, vol. 5, 3 September 2014 (2014-09-03), XP093005846, DOI: 10.3389/fimmu.2014.00423
- See also references of WO 2020223550A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
DOCDB simple family (publication)
WO 2020223550 A1 20201105; AU 2020266595 A1 20211125; BR 112021021843 A2 20220215; BR 112021021843 A8 20220621; CA 3135531 A1 20201105; CN 114072157 A 20220218; EP 3962497 A1 20220309; EP 3962497 A4 20230118; GB 2600834 A 20220511; IL 287650 A 20211201; JP 2022531325 A 20220706; KR 20220045930 A 20220413; MX 2021013355 A 20220221; SG 11202111985X A 20211129
DOCDB simple family (application)
US 2020030837 W 20200430; AU 2020266595 A 20200430; BR 112021021843 A 20200430; CA 3135531 A 20200430; CN 202080048311 A 20200430; EP 20798060 A 20200430; GB 202115849 A 20200430; IL 28765021 A 20211028; JP 2021564784 A 20200430; KR 20217038628 A 20200430; MX 2021013355 A 20200430; SG 11202111985X A 20200430